abstract |
The present invention relates to a HER2 targeting 4-1BB agonist, in particular a 4-1BBL trimer-containing antigen binding molecule comprising at least one antigen binding domain capable of specifically binding to HER2, and its use in cancer treatment, and its T cell activation Relates to the use of anti-CD3 bispecific antibodies in combination. |